Celgene has a 52-week low of $83.16 and a 52-week high of $138.89. The company recently lifted its long-term targets-going out to 2020-to earnings of $13 a share and revenue of $21 billion.
Advertisement
Piper Jaffray’s healthcare analyst Joshua Schimmer weighed in today with a favorable report on Celgene Corporation (NASDAQ:CELG), raising the price target to $160 (from $147) and reiterating an Overweight rating on the stock. Analysts at BMO Capital Markets reiterated a “buy” rating on shares of Celgene in a research note on Thursday.
The average broker recommendation is arithmetical average of the individual ratings contributed by sell-side analysts to produce a Consensus Analyst Rating for each stock. Celgene Corporation (CELG)’S monthly performance stands at 15.660% and has an analyst rating of 1.9. The stock’s 50-day moving average is $117.19 and its 200-day moving average is $117.31. On a consensus basis, analysts have a one year target price of 143.67 on the equity. The company has a market cap of $106,694 million and the number of outstanding shares have been calculated to be 793,144,000 shares. The company said that percentage reflects volume growth in both the U.S. and Europe. Second quarter total revenue increased 22 percent to $2,278 million compared to $1,873 million in the second quarter of 2014. Our consensus called for EPS of $1.08 and the company reported EPS of $1.08 (including stock-based compensation expenses and tax adjustments). Celgene continues to expect adjusted earnings per share (excluding stock-based compensation) in the range of $4.75 to $4.85 per share in 2015. Revimid, the company’s blockbuster treatment for patients suffering from multiple myeloma, is expected to generate sales of a hefty $1.42 billion in the recent quarter, which would represent a 17.1% YoY increase compared to revenues of $1.21 billion reported for 2QFY14. The Summit, New Jersey-based company signed more licensing deals last year than any other biotech drugmaker – 10 in all, according to data compiled by Bloomberg Intelligence. Daniel sold 30,156 shares of Celgene stock in a transaction that occurred on Monday, July 13th. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Gilla Kaplan sold 15,000 shares of Celgene stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $120.78, for a total value of $3,642,241.68. Its primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. The Company’s preclinical and clinical-stage pipeline includes Oral anti-inflammatory agents, OTEZLA (NASDAQ:CELG); Next generation thalidomide analogues, CC-122 and CC-220; Cellular therapies, PDA-001 and PDA-002; CC-486; Sotatercept and ACE-536; mTOR pathway inhibitors, CC-223 and CC-115; Epigenetic modifiers, EPZ-5676 and CC-292. Over the last year and a half, the company has collaborated with Juno Therapeutics and OncoMed Pharmaceuticals. Its subsidiaries are Celgene Avilomics Research and Celgene Cellular Therapeutics.
Advertisement
To view Vetr’s full report, visit Vetr’s official website.
